Shannon M. Matulis - Concepedia

Author

Shannon M. Matulis

Emory University ORCID

Also Known As

S M Matulis, S.M. Matulis, Shannon M Matulis, Shannon M. Matulis, Shannon Matulis

157

Publications

1.8K

Citations

H-Index

Concepts

All Affiliations

Emory University Florida International University University of Miami Roswell Park Comprehensive Cancer Center Northwestern University

About

Shannon M. Matulis is an author at Emory University specializing in medicine, pharmacology, and bioanalysis.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	9	9	468
2	Biochemistry	4	4	117
3	Cell Biology	3	3	148
4	Engineering	2	2	26
5	Natural Sciences	1	1	11

Shannon M. Matulis

Publications

1.6K

Citations

H-Index

Page 1

	Year	Citations
Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia Adriana E. Tron, Matthew A. Belmonte, Ammar Adam, Nature Communications	2018	479
Dexamethasone treatment promotes Bcl-2 dependence in multiple myeloma resulting in sensitivity to venetoclax Shannon M. Matulis, Vikas A. Gupta, A K Nooka, Leukemia Hematological MalignancyLymphoid NeoplasiaAutoimmune DiseaseBcl-2 DependenceHematology	2015	132
Distribution of Bim determines Mcl-1 dependence or codependence with Bcl-xL/Bcl-2 in Mcl-1–expressing myeloma cells Alejo A. Morales, Metin Kurtoğlu, Shannon M. Matulis, Blood	2011	128
Bone marrow microenvironment–derived signals induce Mcl-1 dependence in multiple myeloma Vikas A. Gupta, Shannon M. Matulis, Jason E. Conage‐Pough, Blood	2017	109
Targeting glutamine metabolism in multiple myeloma enhances BIM binding to BCL-2 eliciting synthetic lethality to venetoclax Richa Bajpai, Shannon M. Matulis, Changyong Wei, Oncogene Hematological MalignancyGlutamine MetabolismMedicineMalignant Blood DisorderImmunology	2015	98
Electron transport chain activity is a predictor and target for venetoclax sensitivity in multiple myeloma Richa Bajpai, Aditi Sharma, Abhinav Achreja, Nature Communications	2020	95
MLN4924, an NAE inhibitor, suppresses AKT and mTOR signaling via upregulation of REDD1 in human myeloma cells Yanyan Gu, Jonathan L. Kaufman, Leon Bernal, Blood	2014	78
Venetoclax sensitivity in multiple myeloma is associated with B-cell gene expression Vikas A. Gupta, Benjamin G. Barwick, Shannon M. Matulis, Blood	2021	78
In Silico Modeling-based Identification of Glucose Transporter 4 (GLUT4)-selective Inhibitors for Cancer Therapy Rama K. Mishra, Changyong Wei, Richard C. Hresko, Journal of Biological Chemistry Molecular DockingCancer TherapySilico Modeling-based IdentificationDrug TargetBiochemistry	2015	67
Darinaparsin induces a unique cellular response and is active in an arsenic trioxide-resistant myeloma cell line Shannon M. Matulis, Alejo A. Morales, Lucy Yehiayan, Molecular Cancer Therapeutics	2009	45

Page 1